News Release 

The FASEB Journal: PML as potential treatment for pancreatic cancer

Research reveals high expression and sumoylation of PML as potential treatment for pancreatic cancer

Federation of American Societies for Experimental Biology

A recent study in The FASEB Journal identifies a new mechanism of pancreatic tumors' resistance to chemotherapeutic treatment. The mechanism involves the loss of function of promyelocytic leukemia protein (PML), which operates like a tumor suppressor. Surprisingly, researchers found that the PML dysfunction was due not to a genetic mutation or altered gene expression, but rather to an alteration of a specific type of protein modification.

To conduct the experiment, researchers first generated protein modification profiles of resistant and non-resistant cells from a pancreatic cancer cell line. By comparing the profiles, they identified specific alterations of protein modifications associated with the resistant cells. Among the resistant cells was PML, known for its involvement in an aggressive form of leukemia. Using cultured cells, the current study revealed that an altered modification of PML known as sumoylation was also involved in pancreatic cancer cells' resistance to chemotherapeutic treatment.

Using patient-derived xenografts (i.e., human tumor samples implanted in mice), researchers observed that patients with both high expression of PML and high sumoylation of PML had better rates of survival. Conversely, the study showed that patients with either low expression of PML or low sumoylation of PML had worse rates of survival, as their tumors displayed resistance to chemotherapeutic treatment.

"These findings could improve the prognosis of pancreatic cancer patients in a relatively short period of time," said Philippe Soubeyran, PhD, a researcher at the Marseilles Cancer Research Center (CRCM), National Institute for Health and Medical Research (INSERM) in France. "In the long term, we may be able to improve pancreatic cancer treatments by restoring their efficacy over resistant tumors."

"That a post-translational modification of this protein is so determinative is an intriguing finding," said Thoru Pederson, PhD, Editor-in-Chief of The FASEB Journal. "It not only resets the therapeutic dimension but may herald similar oncoprotein events in other malignancies," he said.

###

The FASEB Journal is published by the Federation of the American Societies for Experimental Biology (FASEB). The world's most cited biology journal according to the Institute for Scientific Information, it has been recognized by the Special Libraries Association as one of the top 100 most influential biomedical journals of the past century.

FASEB is composed of 29 societies with more than 130,000 members, making it the largest coalition of biomedical research associations in the United States. FASEB's mission is to advance health and well-being by promoting research and education in biological and biomedical sciences through collaborative advocacy and service to member societies and their members.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.